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Abstract: Intracellular lipid-binding proteins are a family of low-molecularweight single-chain polypeptides that form 1:1 complexes with fatty acids, retinoids, or other hydrophobic ligands. These proteins are products of a large
multigene family of unlinked loci distributed throughout the genome. Each
lipid-binding protein exhibits a distinctive pattern of tissue distribution. Transcriptional control, regulated by a combination of peroxisome proliferator activated receptors and CCAAT/enhancer-binding proteins, allows for a variety of
both cell and tissue-specific expression patterns. In some cells, fatty acids increase the expression of the lipid-binding protein genes. Fatty acids, or their metabolites, are activators of the peroxisome proliferator–activated receptor family
of transcription factors. Therefore, as the concentration of lipid in the diet increases, the expression of lipid-binding proteins coordinately increases. As revealed by X-ray crystallography, the lipid-binding proteins fold into β-barrels,
forming a large internal water-filled cavity. Fatty acid ligands are bound within
the cavity, occupying only about one-third of the accessible volume. The bound
fatty acid is stabilized via a combination of enthalpic and entropic forces that
govern ligand affinity and selectivity. Cytoplasmic lipid-binding proteins are the
intracellular receptors for hydrophobic ligands, delivering them to the appropriate site for use as metabolic fuels and regulatory agents.
Keywords: fatty acids, carrier proteins, peroxisome proliferator–activated receptors, dietary fat, gene expression
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noids and vitamin A derivatives. To avoid overlap with Li & Norris’s discussion of the intracellular retinoid-binding proteins (69), this review focuses on
the fatty acid–binding members of the gene family and touches on retinoidbinding proteins and their genes only as they relate to the fatty acid–binding
proteins. This review summarizes current knowledge of the structure and genetics of lipid-binding proteins in hopes that it may foster new insights into
the functional aspects of these fascinating proteins.
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INTRODUCTION
Ockner et al’s 1972 paper entitled “A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues” (81) is generally credited with providing the impetus for studies of the structure, function, and regulation of the intracellular lipid-binding protein multigene family.
Some 25 years later, the number of contributions to the literature has grown
to 1500. The diversity of topics ranges from high-resolution X-ray crystallographic analysis of the fatty acid–binding proteins and the role(s) of weak
forces in lipid binding to molecular genetic studies of the linkage between
polymorphisms in the intestinal fatty acid–binding protein gene and diabetes. Popular textbooks now contain information concerning intracellular fatty
acid–binding proteins in lipid metabolism, and scientific meetings are organized around the topic.
Because dietary fats typically constitute over 30% of the caloric intake,
the metabolic relationships between intracellular fatty acid–binding proteins
and the trafficking of nutritionally derived lipids remains an active area of
research. The flux of fatty acids into, out of, and between cells is emerging
as a key facet of information transfer between cells. Fatty acids function not
only as components of membranes or storage depots but also as critical signaling molecules playing fundamental roles in areas such as differentiation,
development, and hormone action. Transgenic animals lacking certain fatty
acid–binding proteins exhibit altered expression of lipid-regulated genes, suggesting the involvement of lipid-binding proteins in signal transduction (42).
These examples point out the close association between nutrient sensing and
cytoplasmic carrier proteins of dietary lipids.
As Ockner’s paper indicated, a variety of tissue and cell types express intracellular lipid-binding proteins. Analysis of the organization of lipid-binding protein genes indicates an evolutionary relationship among the proteins
and points toward extensive gene duplication events as the origin of the many
different family members. To date, at least 23 members of the intracellular
lipid-binding protein multigene family have been described; some preferentially bind fatty acids or related compounds while others associate with reti-
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FATTY ACID–BINDING PROTEIN GENE ORGANIZATION
Genomic Organization and Structure
Somatic cell hybrids and restriction fragment length polymorphisms
(RFLP) have been used to determine the chromosome locations of many fatty
acid–binding protein (FABP) genes (Table 1; see also 12, 36, 39, 82, 86, 112,
118). At least in humans and mice, the genes encoding FABPs are dispersed
throughout the genome. There appear to be no linkages between any of the
genes for fatty acid– and retinoid-binding protein genes.
The gene structure of the FABP family has been conserved amongst all
members studied thus far (Figure 1; 33, 45, 78, 87, 114, 118; AV Hertzel, DA
Bernlohr, manuscript in preparation). Each gene contains four exons separated
by three introns. Although the length of the introns varies, the length of the exons has been maintained such that the positions of the introns within the genes
are essentially identical. Furthermore, this conservation of gene structure for the
FABPs is also maintained in other members of the lipid-binding protein multigene family. For example, the cellular retinol binding protein and cellular retinoic acid binding protein genes all have four exons and three introns, although
the average length of the introns far exceeds that of the FABP genes (69).
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Evolutionary Relationships and Species Considerations
FABPs have been discovered in many organisms, including humans, cows,
pigs, mice, rats, rabbits, guinea pigs, fish, chickens, worms, sharks, frogs, and
insects (121, 125a). The orthologous FABP genes expressed in any given tissue appear to be conserved throughout the various organisms. For example, the liver FABPs from mice and humans are more closely related to each
other than to other mouse and/or human FABPs. One exception is shark liver
FABP: It appears to resemble rat heart FABP more than rat liver FABP (72).
The presence of so many different but highly related genes probably originates from a series of duplications from a common ancestral gene. A complete
analysis of the evolutionary relatedness of proteins in the FABP family has indicated the relative similarity of these proteins and has identified the positions
of gene duplications, of which at least 14 appear (101). Only two of these duplications took place after the divergence of invertebrates from vertebrates.
FATTY ACID–BINDING PROTEIN GENE EXPRESSION

Figure 1 Comparison of the structures of the genes for fatty acid–binding proteins. E, Exon; I, intron. The numbers in the boxes indicate the number of amino acids encoded within each exon.
The bold lines represent the 5′ and 3′ nontranslated portions of exon 1 and exon 4, respectively,
which are of variable lengths. The intron lengths are in kilobase pairs. ALBP, Murine adipocyte
LBP (45, 87); IFABP, murine intestinal FABP (33); LFABP, rat liver FABP (114); myelin P2, murine myelin P2 (78); HFABP, bovine heart FABP (118); KLBP, murine keratinocyte LBP (AV
Hertzel, DA Bernlohr, manuscript in preparation).

Most of the FABP genes exist in a single copy in the genome. Presently,
there are two exceptions: heart HFABP and keratinocyte lipid-binding protein
(LBP). In humans the heart FABP gene seems to be present in a single copy,
whereas the murine heart FABP gene is represented three times, once each on
chromosomes 4, 8, and 10 (39). The copy on chromosome 4 contains three introns, similar to the other FABP genes, and is presumably the functional copy
(118). The gene on chromosome 10 lacks introns and therefore appears to be
a pseudogene. The copy on chromosome 8 may represent a related gene (39).
Southern analysis using the murine keratinocyte LBP cDNA revealed multiple bands for each restriction endonuclease used, suggesting the presence
of five to six copies of the keratinocyte LBP gene (60). Only one copy contains a third intron, suggesting a single functional keratinocyte LBP gene (AV
Hertzel, DA Bernlohr, manuscript in preparation).

Fatty acid–binding proteins are expressed abundantly (1–5% of cytosolic
protein) in cells involved in active lipid metabolism. Although all cells require
fatty acids for membranes, many tissue types such as liver, muscle, and adipose have high flux rates of fatty acids utilized for energy and storage. Members of the FABP family exhibit unique tissue-specific expression patterns and
were named according to the tissue in which each was first identified. Some
show restricted tissue distribution, whereas others are more widespread. For
example, adipocyte LBP (10), intestinal FABP (20), epidermal FABP (105),
myelin P2 (77), brain FABP (62), and testis LBP (also known as PERF15; 83)
are each expressed in a single tissue. Liver FABP (35, 106, 111), ileal LBP
(30, 97), and keratinocyte LBP (60) are expressed in a limited number of tissues. Heart FABP (85, 132) exhibits the broadest tissue distribution occurring
in heart, skeletal muscle, mammary, lung, brain, kidney, testis, ovary, stomach, and adrenal tissues.
FABP genes are expressed in specific cell types within a tissue(s) as a
function of the stage of development or differentiation. For example, intestinal FABP has two gradients of expression within the intestine: a vertical gradient (crypt to villus) and a horizontal gradient (duodenal to colon), with the
highest levels of expression in the jejunum and ileum (33, 121).
Transcription Factors Affecting FABP Expression
Peroxisome proliferators are a group of rodent hepatocarcinogens causing
pleiotropic effects on cell morphology and metabolism. These compounds,
which include plasticizers, herbicides, and the fibrate class of hypolipidemic
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drugs, are considered to be nongenotoxic because they fail to damage DNA
directly. Rather, they may function through an increase in reactive oxygen
species produced by induction of the H2O2-generating peroxisomal enzymes
of the fatty acid oxidation system. Peroxisome proliferators act via peroxisome proliferator–activated receptors (PPARs), a multigene family that is part
of the supergene family of nuclear receptors, such as the thyroid hormone,
retinoic acid, and vitamin D3 receptors (103). There are multiple isoforms of
PPAR in mice (α, γ , and δ) (133) and in Xenopus laevis (α, β, and γ ) (25, 46).
Sequence conservation among PPAR isoforms is highest in the DNA-binding domain, whereas the ligand-binding domain is less well conserved. The
different PPARs bind to hormone response elements (peroxisome-proliferator
response elements, PPREs) of the DR-1 class (TGA/TCCT in a direct repeat
separated by one nucleotide) or to imperfect versions of this element (103).
Binding affinity may be modified by the sequences that flank these elements
(84). PPARs are activated by peroxisome proliferators, hypolipidemic drugs,
and fatty acid metabolites. In a heterologous system using CV1 (monkey kidney) cells, peroxisome proliferators activate PPARα (57). It is thought that
PPARα is involved in lipid catabolism, whereas PPARγ is involved in lipid
anabolism; the function of PPARδ is less well characterized (103).
PPARs bind cooperatively to PPREs as a heterodimer with RXRα (retinoid X receptor), thereby activating gene transcription (59). The ligand for
RXRα is 9-cis retinoic acid. PPARs binds directly to thiazolidinediones (66)
and 15-deoxyΔ12,14-prostaglandin J2 (27, 58). PPARα binds leukotriene B4
with an apparent dissociation constant of 90 nM (23a). Simultaneous exposure to a PPAR activator and 9-cis retinoic acid causes synergistic induction
of gene expression (59).
Although less well characterized, other nuclear receptors, such as LXRα
(ligand X receptor), also dimerize with PPARs (74). This dimerization inhibits PPAR function by reducing the amount of PPAR/RXR heterodimer. Also,
unliganded PPAR receptors may bind DNA and inhibit transcription, perhaps
through co-repressors similar to those that repress the retinoic acid receptor
and the thyroid hormone receptor (15, 40).
Each PPAR isoform exhibits a unique tissue-specific expression pattern as a
result of regulation by various hormones and dietary factors (57). In mice and
rats, the alpha isoform is expressed in liver, kidney, heart, brain, and gut; gamma
is highly restricted to adipose tissue; and delta is expressed ubiquitously. In hepatocytes, steady-state levels of PPARα mRNA are decreased by insulin and
increased by fatty acids and dexamethasone, although no classical hormone
response elements appear to be present in the PPAR promoter (68, 109). Furthermore, PPARα is regulated by a diurnal rhythm paralleling that of corticosterone levels (67). Fasting caused an 80% decrease in PPARγ 2 mRNA levels in
mouse adipocytes, whereas a high-fat diet increased levels by 50% (122).
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Figure 2 Upstream regulatory elements relative to the start of transcription of murine adipocyte
LBP (ALBP; aP2), intestinal FABP (IFABP), heart FABP (HFABP), and rat liver FABP (LFABP).
The arrows indicate the position of transcription initiation. The ALBP upstream region contains a
functional PPAR binding element (DR-1) at −5.3 kb (94, 117), a glucocorticoid response element
(GRE) at −393 to −385 bp (21), a C/EBPα binding site at −149 to −130 (16), and an AP-1 site at
−122 to −116 bp (89). Transcription of the LFABP gene is regulated through three C/EBPα binding sites located at −402 to −385, −356 to −345, and −306 to −275 bp (20, 65). The DR-1 site at
−75 to −66 bp allows responsiveness to peroxisome proliferators through PPARα (47, 106). IFABP is regulated by C/EBPα at −188 to −167 bp (20) and contains putative DR-1 elements at
−591 to −579, −430 to −443, and −82 to −69 (33, 112). HFABP’s putative DR-1 site is located at
−845 bp (118).

In addition to the PPARs, CCAAT/enhancer-binding proteins (C/EBPs;
123) are also involved in the regulation of FABP genes. Many of the FABP
genes contain functional C/EBP-binding sites (Figure 2). C/EBPs comprise
a family of transcription factors that regulate gene expression through binding to the DNA sequence ATTGCGCAAT, although significant substitutions
within this sequence are common (50). These proteins are expressed in tissues
known to metabolize lipids and cholesterol and are thought to play a global
role in the regulation of intermediary metabolism. During cellular differentiation, C/EBPs can affect the transcriptional activities of several genes, which
creates a specialized phenotype leading to the production of a nonproliferating state (120). Several isoforms have been identified based on comparison of
their C-terminal DNA-binding domains (125). This region contains the classical basic region/leucine zipper (bZIP) motif, which allows homodimerization
as well as heterodimerization with other C/EBP family members. An N-terminal transactivation domain presumably functions through interactions with
the transcription machinery. The three isoforms of C/EBP, α, β, and δ, can het-
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erodimerize with one another, bind to similar DNA elements, and transactivate reporter constructs containing C/EBP elements (79).
C/EBPα (expressed in liver, adipocytes, and proliferating myelomonoblasts) coordinates transcriptional activation of groups of genes (11). Although C/EBPα can induce the expression of PPARγ in 3T3-L1 cells, homodimers of C/EBPβ are the primary inducers of PPARγ expression. Both C/EBPβ
and C/EBPδ are necessary but not sufficient for transcriptional activation of
C/EBPα (127).
Insulin reciprocally regulates the transcription of C/EBP genes in adipocytes (70). Treatment of 3T3-L1 adipocytes with insulin inhibits repression
of transcription of the C/EBPα gene. In contrast, insulin treatment rapidly, but
transiently, induces the expression of C/EBPβ and C/EBPδ. Therefore, an increase in insulin level decreases gene expression from promoters with C/EBPbinding sites.
Dietary Control of FABP Expression
The nutritional state of an organism significantly affects FABP expression.
For example, following a 2–3 day fast, liver FABP mRNA decreases 30–70%
in the liver (6); conversely, heart FABP is induced twofold in red skeletal muscle (14). On a low-fat diet, levels of liver FABP and intestinal FABP mRNA
in the intestine decrease, whereas liver FABP mRNA levels remain constant
in the liver (51). Levels of liver FABP in hepatic tissue, normally higher in female than in male mice (4, 7, 80, 85), became similar upon a low-fat diet. In
contrast, a high-fat meal results in a nearly twofold increase in liver FABP
and intestinal FABP (4, 81). In cell culture systems, free fatty acids upregulate
liver FABP expression (19). In addition, long-chain fatty acids rapidly induce
the expression of adipocyte LBP in a variety of preadipocyte cell lines (24).
Therefore, dietary factors, including intake of lipids and fatty acids, affect the
abundance of the FABPs.
Regulation of FABP Genes
ADIPOCYTE LIPID-BINDING PROTEIN (AP2) GENE The adipocyte LBP gene, aP2,
is regulated predominantly during the course of adipose conversion as
cells differentiate from a fibroblastic precursor cell to a mature adipocyte.
Identification of the proteins regulating the increase in expression and the sequence elements to which they bind was facilitated by comparison of the promoter regions of genes induced during adipocyte differentiation (Figure 2).
Fat-specific element 2, bound by a c-fos/c-jun complex, activates transcription of aP2 (89). This sequence, also called AP-1, overlaps a negative regulatory element involved in the control of aP2 expression in preadipocytes. Glu-
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cocorticoids positively regulate aP2 expression, presumably via a response
element identified by sequence analysis at position −393 to −385 (21).
C/EBPα involvement has been demonstrated in the regulation of many
genes that encode proteins of intermediary metabolism. In the promoter region of aP2, C/EBPα binds at −149 to −130 and is a major contributor to the
regulation of gene expression in the mature fat cell (16). Adipocyte response
element 1 (ARE, located at −5.3 kb) is bound by nuclear factor 1 (31). Mutation of this sequence significantly reduced the activation of aP2. ARE2 and
ARE4 (located at approximately −5.2 kb) are two elements that are bound by
ARF2 (adipose regulatory factor 2), and stimulate transcription (32). In cells
in culture, mutation of either site decreases aP2 expression by approximately
90%.
In cell culture, 168 bases of upstream sequence conferred differentiationdependent expression on linked heterologous promoters. However, neither
this nor a larger construct (including 1.7 kb) could direct appropriate expression in transgenic mice. Subsequently, an enhancer was discovered, mapping
at −5.4 kb and −4.9 kb (94). The enhancer alone is necessary and sufficient
to direct adipocyte-specific expression of a reporter gene in transgenic mice.
Within this sequence is a PPRE (DR-1 element) capable of being bound by
the heterodimer PPARγ 2/RXRα (117). The strict tissue-specific expression of
aP2 in adipocytes may be caused by PPAR, which has an expression similar
to that of aP2. The involvement of a PPAR is consistent with the observation
that thiazolidinediones increase aP2 mRNA levels (34). Fatty acids transcriptionally regulate aP2 in preadipocytes but not in mature fat cells to any extent
(24). This observation suggests that in adipocytes, where high levels of adipocyte LBP are present, fatty acids may be relatively ineffective as transcriptional regulators. In summary, many proteins are involved in the regulation of
aP2 expression, including C/EBPα and PPARγ 2.
INTESTINAL FATTY ACID–BINDING PROTEIN GENE

Sequence analysis of the 5´ nontranscribed regions of the intestinal FABP genes from mice, rats, and humans
indicated three highly conserved domains (112). Intestinal FABP is expressed
only in the intestine in a complex pattern of gradients: vertical from crypt to
villus and horizontal from duodenum to colon (20). Reporter constructs in
transgenic mice demonstrated that the first 227 bases upstream of the start of
transcription were capable of directing expression to the small intestine and
displaying the appropriate villus-to-crypt gradient (113). However, 1.1 kb of
sequence is necessary to add the proximal-to-distal pattern as well as to acquire normal levels of expression. The sequence −212 to −188 binds a colonderived factor and is located within a region important to the suppression of
ileal and colonic expression (20).
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DNase I footprinting experiments using C/EBPα resulted in protection of
bases −188 to −167, located within the second of the three conserved domains
of the intestinal FABP promoter (20). A construct containing a C/EBP-binding
site and one DR-1 element was capable of directing expression of intestinal
FABP to the intestine in transgenic animals (20). This DR-1 element is one of
three found in the intestinal FABP promoter (33, 97). The first element binds
a nuclear hormone receptor, ARP-1 (95). Although peroxisome proliferators
have only minimal effects on the expression of intestinal FABP, PPAR/RXR
heterodimers may bind to these elements and activate transcription. As with
other FABPs, C/EBPs and perhaps PPARs appear to be involved in the regulation and tissue-specific expression of intestinal FABP (Figure 2).
LIVER FATTY ACID–BINDING PROTEIN GENE

Liver FABP is expressed abundantly
in the liver (2–5% of cytosolic protein), and in a gradient similar to intestinal
FABP in the intestine (declining gradient from the jejunum to ileum and from
villus tips to crypt cells of villi; 5). Four kilobases of the upstream region of
the liver FABP promotor are sufficient to correctly direct expression of a reporter gene in the hepatocyte. Such a construct is expressed in the horizontal,
but not the vertical, gradient in the intestine (111). Sequences between −4.0
and −0.6 kb are required for suppression of liver FABP expression in the colon and kidney (106).
Both high-fat diets and peroxisome proliferators increase the abundance of
liver FABP in the liver and intestine (52). Consistent with these observations,
the rat liver FABP gene contains an imperfect PPRE at −76 to −66 kb (106).
This sequence confers responsiveness to peroxisome proliferators in the presence of PPARα (47). DNase I footprinting with C/EBPα results in the protection of three distinct regions (20, 65). Therefore, similar to aP2 and intestinal
FABP, the liver FABP promoter contains sequences responsive to both C/
EBPs and PPARs (Figure 2). Unlike other FABPs, liver FABP is able to bind
to peroxisome proliferators, which may play a role in regulating the availability of ligands for PPARs (13).
KERATINOCYTE LIPID-BINDING PROTEIN GENE

Keratinocyte LBP (formerly called
mal-1) was identified as an mRNA that was increased in abundance in murine
benign papillomas and malignant squamous-cell carcinoma of skin (60). Expression of keratinocyte LBP mRNA is low in normal skin, tongue, lung, and
mammary tissue gland. Elevated levels were detected in SV40-transformed
fibroblasts and fibroblasts transformed by other tumor viruses. The rat homolog is highly expressed in lens epithelial cells (124). Keratinocyte LBP is the
first lipid-binding protein to show high levels of induced expression without
concomitant cellular differentiation. Many transformed cells contain altered
types and quantities of lipids in comparison to wild-type cells. Since fatty ac-
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ids regulate other FABPs, it is reasonable to hypothesize that keratinocyte
LBP may respond similarly, perhaps through a PPAR.
In fat cells, the predominant FABP is adipocyte LBP. However, keratinocyte LBP can be detected at very low levels. Spiegelman and colleagues (42)
have developed a line of transgenic mice with a targeted disruption of the aP2
allele. Such animals are fertile, developmentally normal, and phenotypically
indistinguishable from heterozygous littermates. As a result of the aP2 disruption, keratinocyte LBP is induced 40-and 14-fold at the levels of mRNA and
protein, respectively (N Ribarik Coe, AV Hertzel, DA Bernlohr, manuscript
in preparation). Therefore, the lack of aP2 expression is compensated partially by an increase in keratinocyte LBP expression. Consistent with a role of
fatty acids in the regulation of these FABPs, the free fatty acid levels are elevated in adipocytes from transgenic mice null for adipocyte LBP. The altered
intracellular lipid levels may be indicative of metabolic differences between
wild-type and aP2 disruptants. When wild-type animals are fed a high-fat diet
(40% fat calories), diet-induced obesity leads to elevated blood glucose levels, insulin resistance, and overexpression of tumor necrosis factor-α (TNFα). TNF-α indirectly inhibits the tyrosine kinase activity of the insulin receptor, thereby leading to insulin resistance (41). Interestingly, on a high-fat diet,
aP2 null mice had normal blood glucose levels, remained insulin sensitive,
and lacked TNF-α. The observation that elevated dietary fat does not lead to
insulin resistance in aP2 null mice suggests a role for adipocyte LBP in insulin action (42).
CONSERVED ELEMENTS OF THE FABP FOLD
Evolutionary preservation of gene structure between its members is one
reason why the fatty acid–binding proteins are classified as a multigene family. Their overall degrees of nucleotide similarity translate to protein primary sequences ranging in identity from 20 to 70% (Figure 3). Despite such
wide variability in amino acid conservation, crystal structures obtained for
numerous family members have demonstrated a characteristic, superimposable structural arrangement that includes several noteworthy features (22, 99,
128–131).
Measurements of circular dichroism exhibited by the FABPs gave the first
indications of the predominance of β-sheets in the folded protein. Crystallographic analysis indicates the structure is roughly 70% β-sheet conformation. Its topology is relatively simple: ten antiparallel β-strands each hydrogen-bonded to the adjacent strand to form two β-sheets that then fold to adopt
the shape of a barrel (Figure 4). The two sheets are virtually perpendicular to
each other, enabling the first and last β-strands to hydrogen bond and close the
barrel, thus flattening it slightly into what has been described as a β-clam (96).
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Figure 3 Alignment of the amino acid sequences from representative members of each class of
FABP. Dots indicate gaps inserted to optimize alignment. Sequences listed are murine except
where indicated below. The 21 sequences are adipocyte LBP (ALBP), myelin P2 (P2), keratinocyte
LBP (KLBP), human psoriasis-associated FABP (PAFABP), bovine lens LP2 (LP2), heart FABP
(HFABP), brain FABP (BFABP), chick retina (RFABP), rat testis (TLBP), intestinal enterocytes
of rat (IFABP, IBABP) or pig (ILBP), liver FABP (LFABP), shark liver FABP(ShkFABP), human
blood fluke Schistosoma japonicum FABP (SjFABP), blood fluke Schistosoma mansoni (Sm14),
liver fluke Fasciola hepatica (Fh15), and larvae of the moth Manduca sexta (MFB1, MFB2).

The β-strands are interconnected by short loops, each of which contains only
a few amino acids. Between the first and second β-strands two α-helices arranged in a helix-turn-helix motif loop out to cover the mouth of the barrel.
The base of the barrel is filled by side-chains. Located within the barrel is the
large water-filled ligand-binding cavity of about 400–600 Å3 (approximately
2-to 3-fold in excess of the volume required to hold its ligand and 5–10%
of the total protein volume). The cavity wall is lined with amino acid sidechains, roughly 50% of which are charged or polar residues (3).
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Figure 4 Ribbon diagram of adipocyte LBP apoprotein demonstrating characteristic features of
the FABP fold as described in the text. The 10 antiparallel β-strands are labeled βA through βJ.
The α-helices are numbered I and II. Reprinted from Reference 128 with permission from the
American Chemical Society.

As a result of the flattening of the barrel, one pair of adjacent β-strands is
unable to hydrogen bond. There is a gap between strands βD and βE because
of the absence of main-chain hydrogen bonding. In this region the two strands
are oriented such that their side-chains fill much of the interstrand space. Crystallographically ordered water molecules fill the remainder (3). This gap may
result from a preferred folding pathway as dictated by the hydrophobic backbone. The gap is likely to contribute flexibility to the folded structure, in the
sense that it could physically facilitate an opening and closing around larger
ligands, and that the same tertiary structure can be formed despite such varying primary structure.
Space-filling models of the FABPs reveal few sites through which the
binding cavity is accessible to solvent, and none in the static structure with
sufficient dimensions to permit ligand entry. Thus, the region most likely to
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serve as a ligand portal has been deduced by the small amount of exposed
area observable in crystal structures, by its greater mobility (higher B-factors), by its differential sensitivity to proteases in the bound vs unbound state
(49), and by the effect of mutations to that region upon binding affinities/kinetics (17, 37, 56). The portal is gated by the helix-turn-helix motif and interstrand loops βC-to-βD and βE-to-βF. Additional support derives from comparisons of apo-vs holostructures (i.e. unliganded vs ligand bound) in which the
only conformational differences occur in that region (98, 128). Furthermore,
the terminal methyl carbon of oleate protrudes slightly from the small surface
opening (129, 130).
One theory describing probable forces driving protein folding predicts
an initial nonspecific collapse preceding the formation of organized tertiary
structure. Such a collapse is nucleated by interactions between specific nonpolar amino acids that form a hydrophobic core. Searches for motifs of this
kind in the intracellular LBP structures have highlighted a series of primarily nonconsecutive hydrophobic residues that are conserved between family
members (3). These residues cluster to generate a hydrophobic backbone that
may be partly responsible for the basic intracellular LBP fold.
Several of the intracellular LBP crystal structures have been refined
sufficiently to assign coordinates not only to the expected covalent atoms of
the protein and/or bound ligand but also to noncovalently held water molecules (98, 129, 130). These crystallographically ordered waters are conserved
between apo-and holo-structures of the same protein, and to some degree, between proteins. Some of them, as mentioned above, fill portions of the gap not
occupied by side-chain atoms. About ten conserved waters are located within
the cavity such that they form part of the ligand contact site. The conserved
water and polar side-chains are present in the cavity presumably to stabilize
the structure of the protein and to preserve the central ligand cavity. Bound
water may present an attractive force for the acyl tail by taking on a nonpolar
character in the tightly bound state.
FUNCTIONAL ANALYSIS OF THE FABPs
FABPs, as suggested by the name, generally exhibit a preference for fatty
acids. More specifically, only long-chain fatty acids will bind FABPs with
measurable affinity. Each protein molecule will bind and sequester within its
cavity a single hydrophobic ligand. The exception to this is the liver FABP,
which is capable of binding two fatty acids (121).
Affinity for fatty acids appears to be related to chain length, since 16–20
carbon fatty acids have the lowest dissociation constants. Degree of saturation may play a role: Systematic comparison of the binding properties of several FABPs established a correlation between the number of double bonds and
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affinity (91). For certain FABPs, such as liver FABP, affinity decreased with increasing unsaturation. However, for adipocyte LBP, no discrimination in binding between saturated and unsaturated fatty acids was noted. The effect may
arise from the inherent aqueous solubility of the ligand itself, or the number of
polar vs nonpolar cavity contacts with bound ligand, or possibly the degree of
conformational restraint imposed upon the bound ligand by its cavity contacts.
Specificity for ligands in vitro shows some variation among FABP types
(Table 2). Heart, adipocyte, intestinal, keratinocyte, brain, testis, myelin P2,
and liver FABPs are all able to bind tightly to long-chain fatty acids. Adipocyte (MA Simpson, DA Bernlohr, unpublished results) and keratinocyte (55)
LBPs are both able to bind oxidized lipid species such as hydroxy-and hydroperoxyeicosatetraenoic acids (HETEs and HPETEs), but their affinities for
leukotrienes and prostaglandins are negligible. Ileal FABP (97) and intestinal bile acid– binding protein (28) both form high-affinity complexes with
bile acids. Liver FABP, as previously mentioned, can bind either one or two
long-chain fatty acids, but its ligands also include heme, steroids, acyl CoAs,
oxidized/peroxidized fatty acids, leukotrienes, prostaglandins (90), and peroxisome proliferators (108). Brain FABP associates with fatty acids and acyl
CoAs (76).
Besides long-chain fatty acids and other physiological lipids, many of the
FABPs bind fluorescent or sulfonated analogs of fatty acids such as hexadecanesulfonate (63), 1-anilino-8-naphthalenesulfonate (1,8-ANS; 54), 12(9anthroyloxy)oleate (12-AO; 104), 2-(9-anthroyloxy)palmitate (2-AP; 37),
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Figure 5 The FABP fatty acid–binding triad and its interactions with the carboxylate of a bound
ligand. Depicted are amino acids representing adipocyte LBP residues R106, R126, and Y128, as
positioned when bound to stearate. Dotted lines indicate hydrogen bonding. Open symbols represent oxygen, stippled symbols nitrogen, and filled symbols carbon atoms.

and cis-parinaric acid (cPA; 76, 104). Such ligands are particularly useful in
designing assays to evaluate affinity and/or specificity of native ligands.
Numerous crystal structures have been solved in order to study the protein-lipid interactions that determine ligand affinity and specificity on a molecular level. High-resolution crystal structures are available for intestinal
(99), muscle (heart; 130, 131), myelin P2 (22), and adipocyte (63, 64, 128,
129) FABPs in the absence and presence of various ligands. Examination and
comparison of tertiary structures of the holoprotein, in conjunction with primary sequence information, pinpointed three conserved residues that constitute a fatty acid– binding motif. Though the precise conformation of the
hydrocarbon tail varies, similar positions relative to these residues were observed for all structures. As shown in Figure 5, the bound ligand is oriented
such that its negatively charged carboxylate engages in electrostatic-and hydrogen-bonding interactions with two arginines (one via a conserved, crystallographically ordered water) and a tyrosine located at the base of the cavity,
opposite the portal. The tail of the lipid flattens against the wall of the cavity
and either projects with a single bend toward the portal, as observed for adi-
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pocyte LBP binding to oleate, stearate (129), and palmitate (63), or settles into
a U-shape as occurs in heart FABP (130) and adipocyte LBP with bound arachidonate (64). This triad is not preserved in liver, ileal, and intestinal FABPs,
nor in cellular retinol binding proteins I and II (3). The liver and ileal proteins
have broader ligand-binding specificities than most FABPs. Intestinal FABP,
although specific for binding to long-chain fatty acids, retains only a single arginine from the triad motif (99). Cellular retinol binding proteins I and II utilize glutamine at the analogous position to accept a hydrogen bond from the
hydroxyl head group of retinol (22, 126).
Nuclear magnetic resonance (NMR) studies indicated that the carboxylate of ligands bound to intestinal FABP was buried in the cavity, was non-ionizable, and that the signals normally obtained from the single conserved arginine at the base of the cavity were variable with the presence or absence
of a bound ligand (18). NMR data also indicated that ileal (97) and liver (18)
FABPs may bind ligands similarly to each other. Fatty acid carboxylates were
ionizable, indicating solvent accessibility, and were oriented toward the surface of the binding protein. This orientation is opposite that found for intestinal FABP and most other family members.
The importance of the FABP triad was established for adipocyte LBP by
mutagenizing two of its conserved residues, R126 and Y128, to leucine and
phenylalanine, respectively (104). These mutations maintained essentially
similar size and shape characteristics but eliminated hydrogen-bonding and
charge-neutralization capabilities. The mutant protein was no longer able to
bind the fluorescent fatty acid analog cis-parinaric acid, nor would it adhere
to a long-chain fatty acid affinity column (MA Simpson, DA Bernlohr, unpublished results).
Mutagenesis of the intestinal FABP’s conserved arginine was sufficient to
disrupt fatty acid binding as assessed by NMR and titration calorimetry (48).
Furthermore, conversion of this residue to glutamine, as found in the analogous position in cellular retinol binding protein II, converted intestinal FABP
to a retinol-binding protein. Hence, in this family member, a specific arginine
seems to influence ligand specificity.
In contrast, mutation of the analogous arginine 122 residue in liver FABP
altered only slightly the protein’s affinity for fatty acids (116). Instead, its
affinity for acyl CoA ligands was increased. Ligands bound to liver FABP may
have a greater number of nonpolar cavity contacts than ligands bound to other
FABPs. Hydrophobic interactions would then contribute more significantly to
binding energy than would electrostatics.
Energetic Considerations
Titration calorimetry is a technique by which stoichiometry, affinity, and
heat of reaction (enthalpy) may be determined simultaneously for a binding
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interaction. With this information, the free energy and entropy of binding are
then also calculable. Measurements of this kind have been conducted on adipocyte and intestinal FABPs with various ligands (48, 61, 64, 73). Dissociation constants obtained in these studies are approximately an order of magnitude larger than those assessed using fluorescent probes such as 1,8-ANS
(54) and ADIFAB (acrylodan-derivatized intestinal FABP; 91). The acrylodan
moiety displays a fluorescence red shift upon ligand binding, which permits
quantitation of free ligand. This probe can then be used to determine binding
constants for any ligand to any FABP by using a competition assay. Comparison of ADIFAB dissociation constants (Kd) measured at different temperatures yields an alternative enthalpy determination via the van’t Hoff equation.
Despite differences in absolute dissociation constants, which probably arise
because of incorrect reference heat subtractions in the older calorimetric measurements (61), the same conclusions are ultimately derived from the data and
represent consistent information about forces critical to binding. In general,
the affinities of fatty acids for FABPs range from 10 to 1000 nM.
Electrostatic interactions consist of charge neutralizations, hydrogen
bonding, and London dispersion forces (van der Waals interactions). These
interactions contribute primarily to the enthalpy of binding. Thermodynamic
measurements have determined that under physiological conditions, a large
negative enthalpy (i.e. an exothermic reaction) is the major driving force for
the binding reaction. Large enthalpic factors arise from the polar interactions
at the carboxylate, as well as the temporary induced dipoles generated between the long hydrocarbon tail and its cavity contacts. This latter factor, the
van der Waals interaction, partially explains the specificity of FABPs for longchain fatty acids since there is more potential for cavity contact and, therefore, attractive forces.
A small entropic component also contributes to binding energetics. Entropy of binding results from the net balance of unfavorable entropy introduced by the protein constraining the free ligand to a rigidly bound state and
the favorable release of water molecules that formerly were ordered around
the lipid. Therefore, saturated ligands may exhibit a greater positive entropic
effect because of their lower aqueous solubility and the greater amount of disorder that arises when they are removed from solvent.
Recent studies focusing on the kinetic aspects of ligand binding have afforded further physical knowledge about FABP ligand-binding processes. Using a more sensitive mutant of the fluorescent probe ADIFAB, Richieri et
al (92) have compared on-and off-rates for adipocyte, heart, and intestinal
FABPs. The adipocyte protein had the lowest rate constant for ligand binding (kon) and the highest rate of dissociation (koff) for palmitate, oleate, linoleate, linolenate, and arachidonate. Variability in affinities between proteins
and different ligands resulted primarily from differences in koff. Support for
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involvement of the portal derives from a recent study of a variant of intestinal FABP that lacks the helix-turn-helix cap (17, 56). This mutant folded correctly, with some loss of stability (56), and had diminished affinity for fatty
acids that was attributed primarily to an increase in ligand off-rate, while kon
remained unchanged (17). Hence, it seems that ligand binding to FABPs, traditionally considered a two-state process involving only bound or free protein, may transpire via passage through one or more intermediate states.
Kinetic studies have been used for several years to define the putative interactions that might govern transfer of ligands from FABPs to cellular membranes (110). In these experiments, a FABP (heart, adipocyte, liver, or intestinal) was loaded with a fluorescent fatty acid analog and incubated with
phospholipid vesicles of defined composition. Transfer was measured as a
fluorescence decrease when the fatty acid analog entered the vesicle membrane. The rate of transfer from the adipocyte, heart, and intestinal FABP depended on phospholipid composition and vesicle concentration. This observation indicates that collision of the protein with the membrane is required for
lipid transfer (37, 38). Transfer from liver FABP occurs independently of either phospholipid composition or vesicle concentration and so is defined as
diffusional (43). Global acetylation of surface lysine residues of both heart
and adipocyte FABPs altered the kinetics of transfer to a diffusional mechanism and abolished the tendency of both proteins to transfer lipids more rapidly to negatively charged vesicles (37, 38), implicating the lysines in a pivotal role as collisional modulators. Mutants of heart FABP were constructed
that neutralized the lysines at the portal and at regions remote from the portal
(37). Only the neutralized portal lysines affected the transfer mechanism. The
different mechanisms are particularly interesting in intestinal enterocytes, in
which both liver and intestinal FABPs are found, implying that each may have
a specialized function.
HYPOTHESES CONCERNING FABP FUNCTIONS
Fatty acid–binding proteins have been studied for 25 years. Despite our
understanding of the biophysics and molecular genetics of fatty acid–binding proteins, questions remain surrounding their function. X-ray and NMR
structures have provided a wealth of information concerning the physical factors that contribute to ligand binding affinity and specificity. Although transgenic animal studies have been informative, they have not yielded definitive
conclusions concerning the physiological function and role of FABPs in lipid
metabolism.
One suggested role for FABPs is sequestration of fatty acids within the cytosol. FABPs may serve as intracellular buffers for fatty acids, protecting cells
from deleterious effects of excess free fatty acids by sequestering them inside the ligand cavity. This could include a more specific role in scavenging
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of potentially mutagenic reactive lipid species, particularly in the case of liver
FABP and keratinocyte LBP.
FABPs are probably also involved in shuttling fatty acids within the cytosol and delivering them to specific enzyme/protein systems. They may facilitate fatty acid uptake/efflux through the plasma membrane and delivery to
or export from intracellular organelles. This function could also modulate the
fatty acid– sensitive acitivities of some enzymes. A related role is the possible
delivery of lipids to the nucleus, where they may become cofactors for gene
expression mediated by PPARs. In fact, liver FABP translocates from the cytosol to the nucleus in response to ligand binding (108).
Support for the importance of FABPs in uptake and metabolism of fatty
acids derives from studies of the Pima Indians of Arizona. The Pima population has an enhanced predisposition to type II diabetes [non-insulin–dependent diabetes mellitus (NIDDM)] (115). A polymorphism in intestinal FABP
segregates with the disease state, manifested by increased lipid oxidation
and development of obesity and insulin resistance (2). The allele, which encodes a substitution of alanine 54 to threonine, occurs at a frequency of 30%
within the Pima tribe. In vitro, A54T intestinal FABP binds fatty acids twice
as tightly as the wild type. Expression of A54T intestinal FABP in the intestinal epithelial cell line, Caco2, resulted in increased fatty acid uptake and triacylglycerol secretion by these cells (1). Since elevated plasma triacylglycerols are linked to development of insulin resistance, the A54T intestinal FABP
polymorphism could account for the prevalence of insulin resistance in the
Pima Indians.
It is clear that nutritionally derived fatty acids are bound by intracellular
fatty acid–binding proteins (122a). As more negative effects of dietary fat are
revealed, understanding the structure, function, and regulation of cellular lipid
carriers becomes increasingly important. Clues to the involvement of FABP
function in metabolism of dietary lipids come from analysis of altered genetic
states, such as that observed in the Pima Indians or mice null for aP2. In the
Pimas, increased lipid uptake and binding conferred by the intestinal FABP
A54T polymorphism correlates with enhanced prevalence of NIDDM, while
mice lacking adipocyte LBP maintain insulin sensitivity. As we learn more
about the roles of different FABPs, other metabolic processes central to nutrition and human health will likely be uncovered.
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